For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Name:	us-gaap_DueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Note 4 - Advances to CEN Biotech Ukraine (Details Textual) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Dec. 14, 2017	Dec. 02, 2017
XN Pharma [Member] \| CEN Biotech Ukraine [Member]
Ownership Percentage	49.00%		49.00%
CEN Biotech Ukraine [Member]
Due from Related Parties, Total	$ 1,065,328	$ 1,065,328
Percentage of Related Party's Equity Interest Owned by Director				51.00%
CEN Biotech Ukraine [Member] \| Bahige (Bill) Chaaban [Member]
Percentage of Related Party's Equity Interest Owned by Director	25.50%
CEN Biotech Ukraine [Member] \| Usamakh Saadikh [Member]
Percentage of Related Party's Equity Interest Owned by Director	25.50%